|
Region
|
Sample
|
Source
|
155391G & 155391G/A
|
155391A
|
OR
|
P
|
|---|
|
Guangdong
|
Healthy subjectsa
|
TW
|
743
|
697
|
1
| |
| |
EBV-free tumor#
|
TW
|
24
|
15
|
0.67†
|
0.257
|
| |
NHL‡
|
TB
|
8
|
5
|
0.67†
|
0.582
|
| |
HL
|
TB
|
7
|
3
|
0.46†
|
0.345
|
| |
Lymphoma (NHL + HL)
|
TB
|
15
|
8
|
0.57†
|
0.213
|
| |
NPC
|
TB
|
22
|
100
|
8.35˄
|
<0.001
|
|
Shandong
|
Healthy subjectsa
|
TW
|
578
|
34
|
1
| |
| |
EBVaGC
|
TB
|
10
|
0
|
0†
|
1.000
|
| |
NPC
|
TB
|
23
|
13
|
Inf˅
|
0.042
|
-
NHL non-Hodgkin’s lymphoma, HL Hodgkin’s lymphoma, EBVaGC EBV-associated gastric carcinoma. Other abbreviations as in Tables 1 and 2
-
aHealthy subjects from the discovery and replication stages were combined
-
#EBV-free tumors included lung cancer, liver cancer, colorectal cancer, and pancreatic cancer, among others, which were not associated with EBV
-
‡NHL included Burkitt’s and NK/T-cell lymphomas
-
†The frequency of RPMS1 SNP G155391A in healthy subjects from the same region was considered as a reference, with Fisher’s exact test performed
-
˄Lymphoma was considered as a reference
-
˅EBVaGC was considered as a reference
